論文

In a recently published cohort of MM patients, seropositivity was demonstrated at a rate of 56% following the first dose of COVID-19 vaccine, with patients not in complete response or very good partial response at a higher risk for seronegativity as well as those with immunoparesis and more prior treatment lines. Any therapy but no specific treatment was associated with seronegativity. Comparably we demonstrated seropositivity in 76% of MM patients following vaccination with two doses.